pxlence (pronounced 'pixel-ence') is a medical technology company developing and manufacturing PCR assays and kits for targeted resequencing or nucleic acid quantification. pxlence was created as a spin-off company from Ghent University in 2015. We identify unmet needs in the detection of patients’ genetic defects and apply innovative solutions. We combine unique expertise in PCR design and multiplex amplification with leading industry knowledge.

Using our state-of-the-art high-throughput primer design pipeline, one million PCR assays for targeted resequencing of DNA from fresh frozen or formalin fixed paraffin embedded (FFPE) tissue covering 99% of the human exome were expertly designed. These best-in-class assays enable the enrichment of any exonic region of interest for targeted resequencing (discovery) or for confirmation of variants by means of Sanger or massively parallel sequencing (NGS). The assays are also used for pedigree analysis of variants of unknown significance. More than 10,000 different assays for 500 disease genes have been successfully tested in diagnostic laboratories (ISO 15189).

Using our single-tube multiplex PCR and sequencing library preparation technology, a 50-SNP Human Sample ID Kit was released in 2020, followed by a mini-version covering 13 SNPs in 2022. Most recently, we developed Rainbow DNA detection technology using universal probes for digital PCR and quantitative PCR. Our customers include clinical diagnostic laboratories and medical device companies in the field of PCR based molecular analyses.

Biotechnology

Health Diagnostics

Description

People (3)

Frauke Coppieters

Jo Vandesompele

Jan Hellemans

Jobs